New Insight into the Pathogenesis of Cerebral Small-Vessel Diseases

Stroke

Volumn 48, Issue 2, 2017, Pages 520-527

  Müller, Kristin ^a   Courtois, Gilles ^b   Ursini, Matilde Valeria ^c   Schwaninger, Markus ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

^b CEA GRENOBLE   (France)

^c INSTITUTE OF GENETICS AND BIOPHYSICS ADRIANO BUZZATI TRAVERSO   (Italy)

Author keywords

Alzheimer disease; blood brain barrier; CADASIL; incontinentia pigmenti; transforming growth factor beta

Indexed keywords

ALZHEIMER DISEASE; ANGIOGRAPHY; ARTICLE; CADASIL; CEREBROVASCULAR DISEASE; HUMAN; INCONTINENTIA PIGMENTI; MICROVASCULATURE; MULTIINFARCT DEMENTIA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PALLIATIVE THERAPY; PATHOGENESIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE CELL; X CHROMOSOME INACTIVATION; ANIMAL; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY;

TRANSFORMING GROWTH FACTOR BETA;

ANIMALS; CEREBRAL SMALL VESSEL DISEASES; HUMANS; INCONTINENTIA PIGMENTI; TRANSFORMING GROWTH FACTOR BETA;

EID: 85010843598     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.116.012888     Document Type: Article

References (77)

1. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol. 2010;9:689-701. doi: 10.1016/S1474-4422(10)70104-6.
2. Haffner C, Malik R, Dichgans M. Genetic factors in cerebral small vessel disease and their impact on stroke and dementia. J Cereb Blood Flow Metab. 2016;36:158-171. doi: 10.1038/jcbfm.2015.71.
3. Craggs LJ, Yamamoto Y, Deramecourt V, Kalaria RN. Microvascular pathology and morphometrics of sporadic and hereditary small vessel diseases of the brain. Brain Pathol. 2014;24:495-509. doi: 10.1111/bpa.12177.
4. Goldberg MF. The skin is not the predominant problem in inconti-nentia pigmenti. Arch Dermatol. 2004;140:748-750. doi: 10.1001/ archderm.140.6.748.
5. Ridder DA, Wenzel J, Müller K, Töllner K, Tong XK, Assmann JC, et al. Brain endothelial TAK1 and NEMO safeguard the neurovascular unit. J Exp Med. 2015;212:1529-1549. doi: 10.1084/jem.20150165.
6. Smahi A, Courtois G, Vabres P, Yamaoka S, Heuertz S, Munnich A, et al. Genomic rearrangement in NEMO impairs NF-kappaB activation and is a cause of incontinentia pigmenti. The International Incontinentia Pigmenti (IP) Consortium. Nature. 2000;405:466-472. doi: 10.1038/35013114.
7. Beaufort N, Scharrer E, Kremmer E, Lux V, Ehrmann M, Huber R, et al. Cerebral small vessel disease-related protease HtrA1 processes latent TGF-β binding protein 1 and facilitates TGF-β signaling. Proc Natl Acad Sci U S A. 2014;111:16496-16501. doi: 10.1073/pnas.1418087111.
8. Hamel E. Cerebral circulation: function and dysfunction in Alzheimer's disease. J Cardiovasc Pharmacol. 2015;65:317-324. doi: 10.1097/ FJC.0000000000000177.
9. Hara K, Shiga A, Fukutake T, Nozaki H, Miyashita A, Yokoseki A, et al. Association of HTRA1 mutations and familial ischemic cerebral small-vessel disease. N Engl J Med. 2009;360:1729-1739. doi: 10.1056/ NEJMoa0801560.
10. Kast J, Hanecker P, Beaufort N, Giese A, Joutel A, Dichgans M, et al. Sequestration of latent TGF-β binding protein 1 into CADASIL-related Notch3-ECD deposits. Acta Neuropathol Commun. 2014;2:96. doi: 10.1186/s40478-014-0096-8.
11. Wyss-Coray T, Lin C, Sanan DA, Mucke L, Masliah E. Chronic overproduction of transforming growth factor-beta1 by astrocytes promotes Alzheimer's disease-like microvascular degeneration in transgenic mice. Am J Pathol. 2000;156:139-150.
12. Wardlaw JM, Smith C, Dichgans M. Mechanisms of sporadic cerebral small vessel disease: insights from neuroimaging. Lancet Neurol. 2013;12:483-497. doi: 10.1016/S1474-4422(13)70060-7.
13. Brown WR. A review of string vessels or collapsed, empty basement membrane tubes. J Alzheimers Dis. 2010;21:725-739. doi: 10.3233/ JAD-2010-100219.
14. Yang P, Pavlovic D, Waldvogel H, Dragunow M, Synek B, Turner C, et al. String vessel formation is increased in the brain of Parkinson disease. J Parkinsons Dis. 2015;5:821-836. doi: 10.3233/JPD-140454.
15. Zhao Z, Nelson AR, Betsholtz C, Zlokovic BV. Establishment and dysfunction of the blood-brain barrier. Cell. 2015;163:1064-1078. doi: 10.1016/j.cell.2015.10.067.
16. Tikka S, Baumann M, Siitonen M, Pasanen P, Pöyhönen M, Myllykangas L, et al. CADASIL and CARASIL. Brain Pathol. 2014;24:525-544. doi: 10.1111/bpa.12181.
17. Joutel A, Corpechot C, Ducros A, Vahedi K, Chabriat H, Mouton P, et al. Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature. 1996;383:707-710. doi: 10.1038/383707a0.
18. Dziewulska D, Lewandowska E. Pericytes as a new target for pathological processes in CADASIL. Neuropathology. 2012;32:515-521. doi: 10.1111/j.1440-1789.2011.01290.x.
19. Sweeney MD, Ayyadurai S, Zlokovic BV. Pericytes of the neurovascular unit: key functions and signaling pathways. Nat Neurosci. 2016;19:771-783. doi: 10.1038/nn.4288.
20. Feuerhake F, Volk B, Ostertag CB, Jungling FD, Kassubek J, Orszagh M, et al. Reversible coma with raised intracranial pressure: an unusual clinical manifestation of CADASIL. Acta Neuropathol. 2002;103:188-192. doi: 10.1007/s004010100439.
21. Ghosh M, Balbi M, Hellal F, Dichgans M, Lindauer U, Plesnila N. Pericytes are involved in the pathogenesis of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Ann Neurol. 2015;78:887-900. doi: 10.1002/ana.24512.
22. Dichgans M, Mayer M, Uttner I, Brüning R, Müller-Höcker J, Rungger G, et al. The phenotypic spectrum of CADASIL: clinical findings in 102 cases. Ann Neurol. 1998;44:731-739. doi: 10.1002/ana.410440506.
23. Chabriat H, Joutel A, Dichgans M, Tournier-Lasserve E, Bousser MG. Cadasil. Lancet Neurol. 2009;8:643-653. doi: 10.1016/ S1474-4422(09)70127-9.
24. Menezes Cordeiro I, Nzwalo H, Sá F, Ferreira RB, Alonso I, Afonso L, et al. Shifting the CARASIL paradigm: report of a non-Asian family and literature review. Stroke. 2015;46:1110-1112. doi: 10.1161/ STROKEAHA.114.006735.
25. Nozaki H, Kato T, Nihonmatsu M, Saito Y, Mizuta I, Noda T, et al. Distinct molecular mechanisms of HTRA1 mutants in manifesting heterozygotes with CARASIL. Neurology. 2016;86:1964-1974. doi: 10.1212/WNL.0000000000002694.
26. Nozaki H, Nishizawa M, Onodera O. Features of cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencepha-lopathy. Stroke. 2014;45:3447-3453. doi: 10.1161/STROKEAHA. 114.004236.
27. Profenno LA, Porsteinsson AP, Faraone SV. Meta-analysis of Alzheimer's disease risk with obesity, diabetes, and related disorders. Biol Psychiatry. 2010;67:505-512. doi: 10.1016/j.biopsych.2009.02.013.
28. Esiri MM, Wilcock GK. Cerebral amyloid angiopathy in dementia and old age. J Neurol Neurosurg Psychiatry. 1986;49:1221-1226.
29. Brown WR, Thore CR. Review: cerebral microvascular pathology in ageing and neurodegeneration. Neuropathol Appl Neurobiol. 2011;37:56-74. doi: 10.1111/j.1365-2990.2010.01139.x.
30. Bailey TL, Rivara CB, Rocher AB, Hof PR. The nature and effects of cortical microvascular pathology in aging and Alzheimer's disease. Neurol Res. 2004;26:573-578. doi: 10.1179/016164104225016272.
31. van de Haar HJ, Burgmans S, Jansen JF, van Osch MJ, van Buchem MA, Muller M, et al. Blood-brain barrier leakage in patients with early Alzheimer disease. Radiology. 2016;281:527-535.
32. Montagne A, Barnes SR, Sweeney MD, Halliday MR, Sagare AP, Zhao Z, et al. Blood-brain barrier breakdown in the aging human hippocampus. Neuron. 2015;85:296-302. doi: 10.1016/j.neuron.2014.12.032.
33. Halliday MR, Rege SV, Ma Q, Zhao Z, Miller CA, Winkler EA, et al. Accelerated pericyte degeneration and blood-brain barrier breakdown in apolipoprotein E4 carriers with Alzheimer's disease. J Cereb Blood Flow Metab. 2016;36:216-227. doi: 10.1038/jcbfm.2015.44.
34. Sengillo JD, Winkler EA, Walker CT, Sullivan JS, Johnson M, Zlokovic B V. Defciency in mural vascular cells coincides with blood-brain barrier disruption in Alzheimer's disease. Brain Pathol. 2013;23:303-310. doi: 10.1111/bpa.12004.
35. Ryu JK, McLarnon JG. A leaky blood-brain barrier, fbrinogen infl-tration and microglial reactivity in infamed Alzheimer's disease brain. J Cell Mol Med. 2009;13(9A):2911-2925. doi: 10.1111/j.1582-4934. 2008.00434.x.
36. Paul J, Strickland S, Melchor J P. Fibrin deposition accelerates neurovas-cular damage and neuroinfammation in mouse models of Alzheimer's disease. J Exp Med. 2007;204:1999-2008. doi: 10.1084/jem.20070304.
37. Cortes-Canteli M, Mattei L, Richards AT, Norris EH, Strickland S. Fibrin deposited in the Alzheimer's disease brain promotes neuro-nal degeneration. Neurobiol Aging. 2015;36:608-617. doi: 10.1016/j. neurobiolaging.2014.10.030.
38. Bell RD, Winkler EA, Singh I, Sagare AP, Deane R, Wu Z, et al. Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature. 2012;485:512-516. doi: 10.1038/nature11087.
39. Gama Sosa MA, Gasperi RD, Rocher AB, Wang AC, Janssen WG, Flores T, et al. Age-related vascular pathology in transgenic mice expressing presenilin 1-associated familial Alzheimer's disease mutations. Am J Pathol. 2010;176:353-368. doi: 10.2353/ajpath.2010.090482.
40. Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci. 2011;12:723-738. doi: 10.1038/nrn3114.
41. Minić S, Trpinac D, Obradović M. Systematic review of central nervous system anomalies in incontinentia pigmenti. Orphanet J Rare Dis. 2013;8:25. doi: 10.1186/1750-1172-8-25.
42. Fusco F, Paciolla M, Conte MI, Pescatore A, Esposito E, Mirabelli P, et al. Incontinentia pigmenti: report on data from 2000 to 2013. Orphanet J Rare Dis. 2014;9:93. doi: 10.1186/1750-1172-9-93.
43. Fusco F, Pescatore A, Steffann J, Royer G, Bonnefont JP, Ursini MV. Clinical utility gene card for: incontinentia pigmenti. Eur J Hum Genet. 2013;21. doi: 10.1038/ejhg.2012.227.
44. Hadj-Rabia S, Froidevaux D, Bodak N, Hamel-Teillac D, Smahi A, Touil Y, et al. Clinical study of 40 cases of incontinentia pigmenti. Arch Dermatol. 2003;139:1163-1170. doi: 10.1001/archderm.139.9.1163.
45. Poziomczyk CS, Bonamigo RR, Santa Maria FD, Zen PR, Kiszewski AE. Clinical study of 20 patients with incontinentia pigmenti. Int J Dermatol. 2016;55:e87-e93. doi: 10.1111/ijd.13060.
46. Meuwissen ME, Mancini GM. Neurological findings in incontinentia pigmenti; a review. Eur J Med Genet. 2012;55:323-331. doi: 10.1016/j. ejmg.2012.04.007.
47. Abe S, Okumura A, Hamano S, Tanaka M, Shiihara T, Aizaki K, et al. Early infantile manifestations of incontinentia pigmenti mimicking acute encephalopathy. Brain Dev. 2011;33:28-34. doi: 10.1016/j. braindev.2010.04.002.
48. Shields WD. Infantile spasms: little seizures, BIG consequences. Epilepsy Curr. 2006;6:63-69. doi: 10.1111/j.1535-7511.2006.00100.x.
49. Hennel SJ, Ekert PG, Volpe JJ, Inder TE. Insights into the pathogen-esis of cerebral lesions in incontinentia pigmenti. Pediatr Neurol. 2003;29:148-150.
50. Shuper A, Bryan RN, Singer HS. Destructive encephalopathy in inconti-nentia pigmenti: a primary disorder? Pediatr Neurol. 1990;6:137-140.
51. Chatkupt S, Gozo AO, Wolansky LJ, Sun S. Characteristic MR fnd-ings in a neonate with incontinentia pigmenti. AJR Am J Roentgenol. 1993;160:372-374. doi: 10.2214/ajr.160.2.8424354.
52. Cartwright MS, White DL, Miller LM 3rd, Roach ES. Recurrent stroke in a child with incontinentia pigmenti. J Child Neurol. 2009;24:603-605. doi: 10.1177/0883073808327835.
53. Pizzamiglio MR, Piccardi L, Bianchini F, Canzano L, Palermo L, Fusco F, et al. Incontinentia pigmenti: learning disabilities are a fundamental hallmark of the disease. PLoS One. 2014;9:e87771. doi: 10.1371/journal. pone.0087771.
54. Arsura M, Panta GR, Bilyeu JD, Cavin LG, Sovak MA, Oliver AA, et al. Transient activation of NF-kappaB through a TAK1/IKK kinase pathway by TGF-beta1 inhibits AP-1/SMAD signaling and apoptosis: implications in liver tumor formation. Oncogene. 2003;22:412-425. doi: 10.1038/sj.onc.1206132.
55. Freudlsperger C, Bian Y, Contag Wise S, Burnett J, Coupar J, Yang X, et al. TGF-β and NF-κB signal pathway cross-talk is mediated through TAK1 and SMAD7 in a subset of head and neck cancers. Oncogene. 2013;32:1549-1559. doi: 10.1038/onc.2012.171.
56. Schmidt-Supprian M, Bloch W, Courtois G, Addicks K, Israël A, Rajewsky K, et al. NEMO/IKK gamma-defcient mice model inconti-nentia pigmenti. Mol Cell. 2000;5:981-992.
57. Courtois G, Smahi A, Israël A. NEMO/IKK gamma: linking NF-kappa B to human disease. Trends Mol Med. 2001;7:427-430.
58. Fusco F, Fimiani G, Tadini G, Michele D, Ursini MV. Clinical diagnosis of incontinentia pigmenti in a cohort of male patients. J Am Acad Dermatol. 2007;56:264-267. doi: 10.1016/j.jaad.2006.09.019.
59. van Loo G, De Lorenzi R, Schmidt H, Huth M, Mildner A, Schmidt-Supprian M, et al. Inhibition of transcription factor NF-kappaB in the central nervous system ameliorates autoimmune encephalomyelitis in mice. Nat Immunol. 2006;7:954-961. doi: 10.1038/ni1372.
60. Herrmann O, Baumann B, de Lorenzi R, Muhammad S, Zhang W, Kleesiek J, et al. IKK mediates ischemia-induced neuronal death. Nat Med. 2005;11:1322-1329. doi: 10.1038/nm1323.
61. Körbelin J, Dogbevia G, Michelfelder S, Ridder DA, Hunger A, Wenzel J, et al. A brain microvasculature endothelial cell-specifc viral vector with the potential to treat neurovascular and neurological diseases. EMBO Mol Med. 2016;8:609-625. doi: 10.15252/emmm.201506078.
62. Maingay-de Groof F, Lequin MH, Roofthooft DW, Oranje AP, de Coo IF, Bok LA, et al. Extensive cerebral infarction in the newborn due to incontinentia pigmenti. Eur J Paediatr Neurol. 2008;12:284-289
63. Wu H, Luo J, Yu H, Rattner A, Mo A, Wang Y, et al. Cellular resolution maps of X chromosome inactivation: implications for neural development, function, and disease. Neuron. 2014;81:103-119. doi: 10.1016/j. neuron.2013.10.051.
64. Chen CJ, Han IC, Tian J, Muñoz B, Goldberg MF. Extended follow-up of treated and untreated retinopathy in incontinentia pigmenti: analysis of peripheral vascular changes and incidence of retinal detachment. JAMA Ophthalmol. 2015;133:542-548. doi: 10.1001/jamaophthalmol.2015.22.
65. Obermeier B, Daneman R, Ransohoff RM. Development, maintenance and disruption of the blood-brain barrier. Nat Med. 2013;19:1584-1596. doi: 10.1038/nm.3407.
66. Kiehl TR, Chow EW, Mikulis DJ, George SR, Bassett AS. Neuropathologic features in adults with 22q11.2 deletion syndrome. Cereb Cortex. 2009;19:153-164. doi: 10.1093/cercor/bhn066.
67. Thompson CS, Hakim AM. Living beyond our physiological means: small vessel disease of the brain is an expression of a systemic failure in arteriolar function: a unifying hypothesis. Stroke. 2009;40:e322-e330. doi: 10.1161/STROKEAHA.108.542266.
68. ten Dijke P, Arthur HM. Extracellular control of TGFbeta signalling in vascular development and disease. Nat Rev Mol Cell Biol. 2007;8:857-869. doi: 10.1038/nrm2262.
69. Sakurai H. Targeting of TAK1 in infammatory disorders and cancer. Trends Pharmacol Sci. 2012;33:522-530. doi: 10.1016/j.tips.2012.06.007.
70. Poittevin M, Bonnin P, Pimpie C, Rivière L, Sebrié C, Dohan A, et al. Diabetic microangiopathy: impact of impaired cerebral vasoreactiv-ity and delayed angiogenesis after permanent middle cerebral artery occlusion on stroke damage and cerebral repair in mice. Diabetes. 2015;64:999-1010. doi: 10.2337/db14-0759.
71. Negishi M, Lu D, Zhang YQ, Sawada Y, Sasaki T, Kayo T, et al. Upregulatory expression of furin and transforming growth factor-beta by fuid shear stress in vascular endothelial cells. Arterioscler Thromb Vasc Biol. 2001;21:785-790.
72. Lemarié CA, Tharaux PL, Esposito B, Tedgui A, Lehoux S. Transforming growth factor-alpha mediates nuclear factor kappaB activation in strained arteries. Circ Res. 2006;99:434-441. doi: 10.1161/01.RES. 0000237388.89261.47.
73. Sun JH, Tan L, Wang HF, Tan MS, Tan L, Li JQ, et al. Genetics of vascular dementia: systematic review and meta-analysis. J Alzheimers Dis. 2015;46:611-629. doi: 10.3233/JAD-143102.
74. Agarwal I, Arnold A, Glazer NL, Barasch E, Djousse L, Fitzpatrick AL, et al. Fibrosis-related biomarkers and large and small vessel disease: the Cardiovascular Health Study. Atherosclerosis. 2015;239:539-546. doi: 10.1016/j.atherosclerosis.2015.02.020.
75. Capone C, Cognat E, Ghezali L, Baron-Menguy C, Aubin D, Mesnard L, et al. Reducing Timp3 or vitronectin ameliorates disease manifestations in CADASIL mice. Ann Neurol. 2016;79:387-403. doi: 10.1002/ ana.24573.
76. Akhurst RJ, Hata A. Targeting the TGFβ signalling pathway in disease. Nat Rev Drug Discov. 2012;11:790-811. doi: 10.1038/nrd3810.
77. Rutten JW, Dauwerse HG, Peters DJ, Goldfarb A, Venselaar H, Haffner C, et al. Therapeutic NOTCH3 cysteine correction in CADASIL using exon skipping: in vitro proof of concept. Brain. 2016;139(pt 4):1123-1135. doi: 10.1093/brain/aww011.